Du KL et al., 2006-06: University of Pennsylvania phase I report of interstitial motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma, 16 canines in preclinical work plus 16 human subjects, with highly variable dose distribution and necrosis.
We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma.
Du KL et al., 2006-06: University of Pennsylvania phase I report of interstitial motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma, 16 canines in preclinical work plus 16 human subjects, with highly variable dose distribution and necrosis. C3. Study type: preclinical canine series plus phase I human trial. N: 16 canines + 16 humans. Country: USA (University of Pennsylvania). Drug: motexafin lutetium, dose not stated in the abstract; interstitial light delivery with measured fluence and oxygen. Funder: NIH NCI R21 CA88064. Conflicts: none declared in the record. Comparator: none (single-arm). Not methylene blue. Study type: uncontrolled series.
